Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Source filing unavailable
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $631.95K | $824.63K |
| Net Income | -$4.97M | -$3.36M |
| EPS Diluted | -$0.10 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
